Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports

PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab

“…In summary, PD-L1 TC expression seems to be a predictive biomarker for unresectable stage III NSCLC patients treated with cCRT and durvalumab ( 12 ). Patients with PD-L1 TC ≥50% may have the most durable and robust OS and PFS benefit from immune checkpoint inhibition consolidation.…”